Switching to fixed-dose bictegravir, emtricitabine, and tenofovir alafenamide from dolutegravir plus abacavir and lamivudine in virologically suppressed adults with HIV-1: 48 week results of a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial
| Autor: | Molina, Jean-Michel, Ward, Douglas, Brar, Indira, Mills, Anthony, Stellbrink, Hans-Jürgen, López-Cortés, Luis, Ruane, Peter, Podzamczer, Daniel, Brinson, Cynthia, Custodio, Joseph, Liu, Hui, Andreatta, Kristen, Martin, Hal *, Cheng, Andrew, Quirk, Erin |
|---|---|
| Zdroj: | In The Lancet HIV July 2018 5(7):e357-e365 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|